Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Knowing what to include helps you prepare quickly. This intro highlights essential categories and a simple framework for an effective emergency budget.
15,405 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
A recently launched XRP-focused ETF aims to deliver 3% monthly income by selling XRP call options, blending crypto ex...
Oil’s surge fuels a wave of gains in key energy ETFs, led by XLE, OIH, and PBT, as supply, demand, and drilling budge...
Investors are weighing a shift from high-growth tech to more income-driven energy plays as AI-era capex creates uncer...
After years of watching this stock trade at lofty valuations, a broad market sell-off finally creates an entry point....
As biotech earnings season unfolds, Precigen (PGEN) 2025 earnings take center stage. This guide breaks down what to m...
A Miami-based fintech has closed a $17 million Series A to speed fiat-to-stablecoin trades for businesses. The round ...
A Bernstein Research note argues Bitcoin has likely formed a cycle bottom and pins a $450 target on Strategy stock, s...
Olaplex shares exploded after Henkel announced a cash buyout. This piece breaks down what happened, why it matters fo...
Meta is plowing ahead with AI investments. This article explains why the reason meta's spending spree could stay on t...
The U.S. shipbuilding industry is looming a 250,000-worker gap over the next decade, even as the Trump administration...
Bank of America has agreed to a $72.5 million settlement in a high-profile Epstein-related civil case, avoiding admis...